| Literature DB >> 27406026 |
Min Yan1,2, Chunli Wang3, Bin He1, Mengying Yang3, Mengying Tong3, Zijie Long4, Bing Liu3, Fei Peng3, Lingzhi Xu3, Yan Zhang1, Dapeng Liang3, Haixin Lei3, Sen Subrata5, Keith W Kelley6,7, Eric W-F Lam8, Bilian Jin9, Quentin Liu10,11,12.
Abstract
The Aurora kinase family is comprised of three serine/threonine kinases, Aurora-A, Aurora-B, and Aurora-C. Among these, Aurora-A and Aurora-B play central roles in mitosis, whereas Aurora-C executes unique roles in meiosis. Overexpression or gene amplification of Aurora kinases has been reported in a broad range of human malignancies, pointing to their role as potent oncogenes in tumorigenesis. Aurora kinases therefore represent promising targets for anticancer therapeutics. A number of Aurora kinase inhibitors (AKIs) have been generated; some of which are currently undergoing clinical evaluation. Recent studies have unveiled novel unexpected functions of Aurora kinases during cancer development and the mechanisms underlying the anticancer actions of AKIs. In this review, we discuss the most recent advances in Aurora-A kinase research and targeted cancer therapy, focusing on the oncogenic roles and signaling pathways of Aurora-A kinases in promoting tumorigenesis, the recent preclinical and clinical AKI data, and potential alternative routes for Aurora-A kinase inhibition.Entities:
Keywords: Aurora kinase inhibitors (AKIs); Aurora-A; mitosis; targeted cancer therapy; tumorigenesis
Mesh：
Substances：
Year: 2016 PMID： 27406026 DOI： 10.1002/med.21399
Source DB: PubMed Journal: Med Res Rev ISSN： 0198-6325 Impact factor: 12.944